GSK and VIR Biotechnology to Evaluate VIR-7832 in the Early Treatment of COVID-19

 GSK and VIR Biotechnology to Evaluate VIR-7832 in the Early Treatment of COVID-19

GSK and VIR Biotechnology to Evaluate VIR-7832 in the Early Treatment of COVID-19

Shots:

  • The companies signed an agreement with to evaluate VIR-7832 vs PBO in P-Ib/IIa AGILE study in patients with mild to mod. COVID-19. The trial is expected to be initiated in Q1’21 across up to five sites in the UK
  • The preclinical data demonstrated that VIR-7832 enhanced ability to clear infected cells and enhance virus-specific T cell function, treating or prevent COVID-19 infection
  • VIR-7832 is a dual-action mAb, currently being evaluated in two global P-III studies for the early treatment of COVID-19 in patients who are at high risk of hospitalization, and for hospitalized patients with COVID-19

Click here ­to­ read full press release/ article | Ref: GSK | Image: Medical Dialogues

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post